Eden vs Henry Meds: Vertically-Integrated Specialist vs Cohort-Cheapest

Who wins for each use case

We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.

• BBB rating and complaint posture

  Winner: Eden

  Henry Meds is NOT BBB-accredited and carries an F letter grade with 192 complaints in three years (25 of which received no business response). The non-response rate is the part that drives the F. Eden's BBB profile is Not Rated with the file open since April 2024, which is also imperfect, but the absence of an F-grade complaint volume is meaningfully better than Henry Meds. Eden wins this row clearly.

• Trustpilot signal credibility

  Winner: Eden

  Henry Meds shows 4.5/5 across roughly 12,300 reviews on Trustpilot, but the page itself carries Trustpilot's suspected-fraudulent-review notice. That fraud notice is Trustpilot's own flag that something about the review pattern looks artificial, and we weight it more heavily than the average. Eden's Trustpilot is 4.5/5 across roughly 3,000 reviews with no fraud notice. Eden's smaller sample is more credible than Henry Meds's larger but flagged sample.

• Manufacturer lawsuit posture

  Winner: Eden

  Henry Meds has an active Eli Lilly lawsuit (4:25-cv-03536, N.D. Cal.) over compounded tirzepatide marketing claims. The personalization-marketing claim survived a September 2025 partial dismissal, so the case is moving forward. Eden has no comparable open manufacturer litigation. Both have other counterweights, but ongoing manufacturer litigation is the heavier signal.

• Vertical integration and per-fill sourcing

  Winner: Eden

  Eden owns the pharmacy that fills its prescriptions, so 'who compounded my dose' is a non-question. Henry Meds uses unnamed compounding-pharmacy partners; specific partner per fill is not disclosed publicly. For users who weight knowing exactly where their compounded medication came from, vertical integration is a meaningfully cleaner answer than per-fill opacity.

• Cash-pay price on oral semaglutide

  Winner: Henry Meds

  Henry Meds starts oral semaglutide around $99/month, materially below Eden and the rest of the cohort. If pure headline price is the only thing you weight and you are comfortable with the trust caveats, this is the cheapest option that exists. The caveat: BBB complaints describe a secondary $49/month subscription disclosed only in the terms of service, so the all-in monthly cost can be higher than the headline. Even with that caveat, Henry Meds wins on this row.

• Oral tirzepatide tablet availability

  Winner: Henry Meds

  Henry Meds offers oral tirzepatide tablets at $349/month month-to-month or $234/month on annual prepay, a relatively rare product line in this category. Eden focuses on injectable semaglutide and tirzepatide and does not carry oral tirzepatide tablets at comparable price. If you specifically want oral tirzepatide, the choice narrows to Henry Meds.

• Privacy posture

  Winner: Henry Meds

  Eden has a class-action investigation specifically about possible undisclosed sharing of sensitive health data with ad-platform pixels (Meta, TikTok). Henry Meds has no comparable open privacy investigation at capture date. For privacy-sensitive users, this row tips Henry Meds, with the caveat that this is one of the only places Henry Meds has a meaningfully cleaner signal than Eden.

• Cancellation friction

  Winner: Eden

  Henry Meds requires a phone call to cancel (no in-app self-serve flow); BBB complaints document a pattern of unanswered calls and continued billing after attempted cancellation. Eden has its own cancellation complaints in the BBB record, but the operational pattern is not as severe as Henry Meds's phone-only-with-unanswered-calls structure. Eden wins this row by a smaller margin.

Pricing in plain terms

Henry Meds: $99/month oral semaglutide, $149-$179/month injectable semaglutide, $349/month oral tirzepatide tablets ($234/month annual prepay), $449/month injectable tirzepatide. Eden: all-inclusive cash-pay program tiers, mid-range for the compounded cohort with the vertical-integration premium baked in. Headline price gap on oral semaglutide is real (Henry Meds ~$99 vs Eden's higher number), but BBB complaints on Henry Meds suggest the all-in cost can be higher than the headline once the secondary $49/month subscription surfaces. For most cost-sensitive readers, Eden's slightly higher monthly cost buys a meaningfully cleaner trust posture; the trust premium is worth paying.